Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE Decision Resources Group
Personalized Drug Treatment Will Emerge for HCC with the Approval of a Novel Biomarker-Targeted Agent, According to Findings from Decision Resources Group
BURLINGTON, Mass., May 7, 2014 /PRNewswire/ -- Decision Resources Group finds that the treatment landscape of hepatocellular carcinoma (HCC) will change dramatically through 2023 as new therapies gain approval and launch for second-line treatment of advanced HCC following disease progression/intolerance to first-line Nexavar (Bayer HealthCare/Amgen/Onyx) treatment. The launch of novel therapies-tivantinib (ArQule/Daiichi Sankyo/Kyowa Hakko Kirin) and Cyramza (Eli Lilly)-for use in the second-line setting will provide treatment options in a patient population for which there is currently no standard of care.
Other key findings from the Niche Markets and Rare Diseases report entitled Hepatocellular Carcinoma:
Comments from Decision Resources Group Senior Analyst Karen Pomeranz, M.Sc., Ph.D.:
About Decision Resources Group
Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. Clients rely on this analysis and data to make informed decisions. Find out more at www.DecisionResourcesGroup.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact:
Decision Resources Group
©2012 PR Newswire. All Rights Reserved.